MAP2K1 and cancer: For instance, there are numerous reports about decreased ERK1/2 phosphorylation in cancer cells following MEK1/2 inhibitor treatment (McDaid et al., 2005; Solit et al., 2006; Ciuffreda et al., 2009; Iverson et al., 2009; Infante et al., 2012), as well as in virus infected cell and animal models (Pleschka et al., 2001; Laure et al., 2020; Koch-Heier et al., 2022; Schreiber et al., 2022).